Can you provide an article on Cannabinoid Hyperemesis Syndrome?

Cannabinoid Hyperemesis Syndrome: Clinical Overview

Definition and Epidemiology

Cannabinoid Hyperemesis Syndrome (CHS) is a disorder of gut-brain interaction characterized by cyclic episodes of severe nausea, vomiting, and abdominal pain occurring in chronic cannabis users, with the pathognomonic feature of compulsive hot water bathing for symptom relief. 1

CHS affects approximately one-third of chronic cannabis users and has become increasingly prevalent in emergency departments following cannabis legalization in North America 2, 3. The typical patient profile includes:

• Mean age: 30 years
• 69% male predominance
• Mean duration of cannabis use before symptom onset: 6.6 years
• Daily use in 68% of cases
• Hot water bathing behavior in 71% of patients 1

Recent survey data demonstrates that 96.5% of CHS patients used cannabis at least daily, with 45% using six or more times per day when symptoms developed 4. The syndrome is associated with substantial healthcare burden, including frequent emergency department visits and hospitalizations 5.

Pathophysiology

The mechanism involves dysregulation of the endocannabinoid system through CB1 receptors. Delta-9-tetrahydrocannabinol (THC) overstimulates CB1 receptors in the dorsal vagal complex of the brain, disrupting the hypothalamic-pituitary-adrenal axis negative feedback loop, resulting in increased vagal nerve discharges that trigger vomiting 1.

THC also binds to transient receptor potential vanilloid type 1 (TRPV1) channels, affecting vagus nerve and gut function. Peripheral CB1 receptor activation impairs gastric motility, emptying, and acid secretion 1.

Diagnostic Criteria

CHS should be suspected in any patient presenting with chronic nausea and vomiting who uses cannabis regularly 1. The formal diagnostic criteria require all three components 1:

1. Clinical Features

• Stereotypical episodic vomiting resembling cyclic vomiting syndrome
• Frequency: 3 or more episodes annually

2. Cannabis Use Patterns

• Duration: More than 1 year of use before symptom onset
• Frequency: More than 4 times per week on average

3. Cannabis Cessation

• Resolution of symptoms after abstinence for at least 6 months, OR
• Abstinence equal to the total duration of 3 typical vomiting cycles

Key Clinical Clues

• Compulsive hot water bathing or showering (though not pathognomonic, as it occurs in 30% of cyclic vomiting syndrome cases) 1
• Morning symptom clustering (63.1% of cases) 4
• Predominant complaints: nausea and stomach pain during prodromal phase 4
• Women report more frequent and prolonged symptoms than men 4

Critical Differential Diagnosis

In the emergency department, immediately exclude life-threatening conditions before attributing symptoms to CHS: 1

• Acute abdomen
• Bowel obstruction
• Mesenteric ischemia
• Acute pancreatitis
• Myocardial infarction

In the outpatient setting after structural abnormalities are excluded, consider: 1

• Cyclic vomiting syndrome (CVS) - can only be differentiated from CHS by establishing remission during 6 months of abstinence 3
• Rumination syndrome
• Gastroparesis
• Pregnancy
• Migraine
• Functional chronic nausea and vomiting syndrome

Management Algorithm

Acute/Emergency Department Management

For acute severe vomiting, haloperidol up to 5 mg intramuscularly is the first-line pharmacologic treatment 3, 6. Additional acute treatment options supported by case series include 1:

• Topical capsaicin 0.075-0.1% cream applied to the abdomen (activates TRPV1 receptors; works less quickly than haloperidol but effective) 3
• Benzodiazepines
• Promethazine
• Olanzapine
• Ondansetron

Critical pitfall: AVOID OPIOIDS - they worsen nausea and carry high addiction risk 1.

Long-Term Management

The definitive treatment is complete and sustained cannabis cessation - this is the ONLY intervention that achieves full remission and cure 1, 3. The management strategy must include:

1. Cannabis Cessation Counseling (Mandatory)

• Emphasize that even low-dose cannabis relapses trigger stronger and longer vomiting episodes than previously experienced (sensitization phenomenon) 3
• The threshold for CHS episodes decreases continuously with repeated clusters (chronification) 3
• Recidivism rates are high (>40% in single-center data) 1

2. Pharmacologic Support

Amitriptyline is the mainstay of long-term pharmacotherapy: 1

• Starting dose: 25 mg at bedtime
• Titrate weekly to minimal effective dose: 75-100 mg at bedtime

3. Adjunctive Topical Therapy

• Topical capsaicin 0.1% cream with close monitoring of efficacy and adverse effects 1

4. Psychiatric Co-Management

Co-management with psychology or psychiatry is indicated for: 1

• Patients lacking response to standard therapies
• Extensive psychiatric comorbidity (anxiety and depression are very common) 1
• Patients who remain uncertain about the role of cannabis despite recurrent episodes 1

Evidence Limitations and Unvalidated Strategies

The following commonly suggested strategies lack scientific validation and should NOT be recommended: 1

• Switching to lower THC/higher CBD formulations
• Using edible forms instead of smoking
• Avoiding THC concentrates

Preliminary evidence suggests fatty acid amide hydrolase inhibitors and CBD may reduce cannabis use in cannabinoid use disorder, but larger studies are needed before clinical recommendation 1.

Cannabis Use Patterns Associated with CHS

CHS is most strongly associated with long-term, frequent use of inhaled THC-dominant cannabis 4. Key risk factors include:

• Vape cartridge use associated with shorter time to symptom development 4
• Smoking and vape cartridges are the most commonly reported consumption methods 4
• Source of cannabis (licensed dispensary vs. other) does not affect syndrome presentation 4
• Heavy daily use and adolescent-onset use increase risk 5

Clinical Pearls

• CHS is classified in Rome IV as a disorder of gut-brain interaction since 2016 1
• Many patients remain uncertain about cannabis's role despite diagnosis, attributing symptoms to food, alcohol, or stress 1
• The syndrome presents an interdisciplinary challenge requiring collaboration between emergency medicine, gastroenterology, psychiatry, and addiction services 3
• Full remission requires at least 5 years of sustained abstinence 3